Next Generation Blood Products Advanced Technology
Abstract
This Project covers technology development, pre-clinical and early-clinical demonstration, and transition of new blood products with increased shelf life and functionality. Cold-stored platelets, fibrinogen replacement technologies, and pharmaceuticals that protect and metabolically stabilize blood-deprived tissues and reverse impaired blood clotting subsequent to severe injury, will improve prompt hemorrhage control, mitigate effects of shock, and minimize sustainment requirements. All research is conducted in compliance with Food and Drug Administration (FDA) requirements for licensure of medical products for human use. Promising efforts identified through Applied Research conducted under PE 0602787A (Medical Technology) Project MM4 (Cbt Casualty Care Applied Rsch Technology) are further matured under this Project. Promising results identified under this Project are further matured under PE 0603807A (Medical Systems Advanced Development) Project 836 (Field Medical Systems Advanced Development). The cited work is consistent with the Under Secretary of Defense (Research and Engineering) science and technology focus areas and the Army Modernization Strategy. All FY20 adjustments align program resources to Army Modernization Priorities in support of the National Defense Strategy. Work in this Project is performed by the United States Army Medical Research Development Command (USAMRDC), Fort Detrick, MD.
Document Details
- Document Type
- Project
- Publication Date
- Oct 01, 2021
- Source ID
- MN5_0603002A_3_2040_PB_2021
Related Documents
- Root: Medical Advanced Technology
- Child Accomplishment: Next Generation Human-Derived Blood Replacement
- Child Accomplishment: FY 2020 SBIR/STTR Transfer